Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Sponsored content

Managing IP’s Asia-Pacific Special Focus 2022 launched

MIP Asia-Pacific Editorial Image.jpg

Managing IP has partnered with IP leaders from across the Asia-Pacific region to analyse recent court cases and analyse incoming regulations in India, Korea, and Japan

Click here to read the full Asia-Pacific Special Focus 2022.

First, our writers from Anand and Anand explore the significance of a recent ruling concerning trademark protection of film titles and assess the tests used to establish the copyrightability of characters.

In the case Sholay Media Entertainment & Anr. v Yogesh Patel & Ors., the Delhi High Court held that “certain films cross the boundaries of just being ordinary words and the title of the film ‘SHOLAY’ is one of them”. In other words, movie titles are entitled to trademark protection, providing they have achieved a secondary meaning.

Next the authors from FirstLaw P.C. analyse the impact of a ruling from the Supreme Court of Korea on the inventiveness standards for certain inventions, which is encouraging for pharmaceutical patentees.

In 2021, the Court departed from precedent in holding that, to determine the inventiveness of a selection invention, the difficulty to conceive the selection invention should first be examined. If difficulty cannot be shown, the inventiveness of the selection invention may then be assessed based on the existence of a remarkable effect of the selection invention.

In March 2022, the Court went further and upheld the inventiveness of a specific crystalline form invention without requiring corroboration of the presence of a remarkable effect of the crystalline form invention. The approach adopted by the Supreme Court is a promising sign for patentees in Korea, especially those in the pharmaceutical industry.

Finally, our contributor from Shiga International Patent Office (JPO) explains why the Japan Patent Office has introduced restrictions on multi-multi claims, and offers advice to domestic and overseas patent applicants.

The JPO intends to enhance global harmonisation and reduce the burden of examinations and monitoring by third parties. For both overseas and Japanese applicants, it is important to be aware of the regulations and take measures to avoid unnecessary costs and obtain a patent efficiently.

Click here to read the full Asia-Pacific Special Focus 2022.

more from across site and ros bottom lb

More from across our site

The easyJet owner’s trademark complaint says the band Easy Life has risked damage to the airline’s reputation through negative publicity
Jessica Kaiser tells Managing IP why she moved to Perkins Coie and how she wants to expand the firm’s PTAB practice
Lawyers at Allen & Overy provide some key takeaways from the UPC’s first few months
Speaking exclusively to Managing IP, Oliver Walsh said he is looking forward to developing cutting-edge enforcement solutions, including AI-powered predictive analysis
Johnson & Johnson won’t enforce patents for bedaquiline after months of public scrutiny and new licences for generics
We have published this year’s Corporate IP Stars list, an annual rankings publication which recognises senior in-house practitioners
The 2023 edition of Managing IP’s Rising Stars publication is now available online
Allison M Hester, attorney at Moye White, outlines Mattel's litigation history and explains what trademark lessons brands can learn from the toy company
The former BoA president won a high-profile race to succeed Christian Archambeau as executive director in July
Each week Managing IP speaks to a different IP professional about their life and career